WIN Consortium to conduct targeted tri-therapy trial for NSCLC
French non-profit healthcare network WIN Consortium (WIN) is set to conduct a clinical trial (SPRING) of a new three targeted therapies combination as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC), following appro …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | France Health | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals